Daylight Exposure During Office Hours Improves Metabolic Health in T2D Patients
In a randomized crossover clinical trial (NCT05263232), Harmsen et al. investigated the metabolic effects of natural daylight exposure during office hours in individuals with type 2 diabetes (T2D). Thirteen participants with T2D, virologically suppressed on treatment, were exposed to either natural daylight (facilitated through windows) or constant artificial office lighting for 4.5 consecutive days in a controlled setting, with interventions separated by a washout period.
Merck Launches Phase 3 KANDLELIT-007 Trial of Calderasib Plus KEYTRUDA QLEX in NSCLC
GSK announced on January 7, 2026, positive topline results from the two pivotal Phase III trials, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), evaluating bepirovirsen, an investigational triple-action antisense oligonucleotide (ASO), as a potential first-in-class finite treatment for chronic hepatitis B (CHB).
GSK’s Shingrix Gains EC Approval for Ready-to-Use Prefilled Syringe
GSK announced that the European Commission (EC) has approved a new prefilled syringe presentation for Shingrix (Recombinant Zoster Vaccine, Adjuvanted; RZV), a key advancement designed to streamline vaccine administration. Previously, Shingrix required reconstitution by mixing a lyophilised powder antigen vial with a liquid adjuvant suspension. The new ready-to-use prefilled syringe eliminates this step, offering healthcare professionals a more convenient option without altering the vaccine’s composition, efficacy, safety profile, indication, or two-dose regimen.
Prof GIUSEPPE MANCIA
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 1
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 2
Professor Dame Anna Dominiczak at ESH 2019 Milan
